65
Participants
Start Date
October 9, 2013
Primary Completion Date
October 24, 2017
Study Completion Date
October 24, 2017
GSK3052230
A clear to opalescent, colorless to pale yellow solution for IV infusion once weekly (Day 1, Day 8, Day 15) in each 21-day cycle with unit dose strengths/dose level of 5, 10, 15, and 20 mg/kg supplied in a sterile 25 mL glass vial.
paclitaxel
paclitaxel will be from commercial stock.
carboplatin
carboplatin will be from commercial stock.
docetaxel
docetaxel will be from commercial stock.
pemetrexed
pemetrexed will be from commercial stock
cisplatin
cisplatin will be from commercial stock
GSK Investigational Site, Koebenhavn Oe
GSK Investigational Site, Leuven
GSK Investigational Site, New York
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Málaga
GSK Investigational Site, Charleston
GSK Investigational Site, Seville
GSK Investigational Site, Columbus
GSK Investigational Site, Detroit
GSK Investigational Site, Chicago
GSK Investigational Site, St Louis
GSK Investigational Site, Duarte
GSK Investigational Site, Sacramento
GSK Investigational Site, Arkhangelsk
GSK Investigational Site, Vsevolozhsk
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Ryazan
GSK Investigational Site, Peoria
GSK Investigational Site, Chapel Hill
GSK Investigational Site, Amsterdam
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Badajoz
GSK Investigational Site, Barcelona
GSK Investigational Site, Barcelona
GSK Investigational Site, Leicester
GSK Investigational Site, London
GSK Investigational Site, Nottingham
Lead Sponsor
GlaxoSmithKline
INDUSTRY